Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1145-1154

  Bannerman, Bret ^a   Xu, Ling ^a   Jones, Matthew ^a   Tsu, Christopher ^a   Yu, Jie ^a   Hales, Paul ^a   Monbaliu, Johan ^b   Fleming, Paul ^a   Dick, Lawrence ^a   Manfredi, Mark ^a   Claiborne, Christopher ^a   Bolen, Joseph ^a   Kupperman, Erik ^a   Berger, Allison ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Activity; Antagonism; Bortezomib; Epigallocatechin gallate; Vitamin C

Indexed keywords

ASCORBIC ACID; BORTEZOMIB; EPIGALLOCATECHIN GALLATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BORONIC ACIDS; CATECHIN; CHROMATOGRAPHY, LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRAZINES; TANDEM MASS SPECTROMETRY; TEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82455175265     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1591-2     Document Type: Article

References (22)

1. ® (bortezomib) for Injection. Prescribing information. Cambridge, MA, USA Issued December 2009, version 10
2. ® (bortezomib). Summary of product characteristics. Beerse, Belgium Issued July 2010
3. J Adams 2004 The development of proteasome inhibitors as anticancer drugs Cancer Cell 5 417 421 15144949 10.1016/S1535-6108(04)00120-5 1:CAS:528:DC%2BD2cXksFCmt7s%3D (Pubitemid 38610244)
4. A Ciechanover 1998 The ubiquitin-proteasome pathway: on protein death and cell life EMBO J 17 7151 7160 9857172 10.1093/emboj/17.24.7151 1:CAS:528:DyaK1MXktl2hsQ%3D%3D (Pubitemid 29002684)
5. M Boccadoro G Morgan J Cavenagh 2005 Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy Cancer Cell Int 5 18 15929791 10.1186/1475-2867-5-18 (Pubitemid 41460748)
6. G Springsteen BA Wang 2002 Detailed examination of boronic acid-diol complexation Tetrahedron 58 5291 5300 10.1016/S0040-4020(02)00489-1 1:CAS:528:DC%2BD38XkvVWktLs%3D (Pubitemid 34663811)
7. W Zou P Yue N Lin, et al. 2006 Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells Clin Cancer Res 12 273 280 16397052 10.1158/1078-0432.CCR-05-0503 1:CAS:528:DC%2BD28Xht1GktQ%3D%3D (Pubitemid 43166204)
8. EB Golden PY Lam A Kardosh, et al. 2009 Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors Blood 113 5927 5937 19190249 10.1182/blood-2008-07-171389 1:CAS:528:DC%2BD1MXnsVSktro%3D
9. G Perrone T Hideshima H Ikeda, et al. 2009 Ascorbic acid inhibits antitumor activity of bortezomib in vivo Leukemia 23 1679 1686 19369963 10.1038/leu.2009.83 1:CAS:528:DC%2BD1MXhtV2rtrjO
10. CN Papandreou DD Daliani D Nix, et al. 2004 Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 2108 2121 15169797 10.1200/JCO.2004.02.106 1:CAS:528:DC%2BD2cXpsVWlsLc%3D (Pubitemid 41095144)
11. P Moreau V Coiteux C Hulin, et al. 2008 Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma Haematologica 93 1908 1911 18768528 10.3324/haematol.13285 1:CAS:528:DC%2BD1MXhtFynur4%3D
12. Reece DE, Sullivan D, Lonial S et al (2010) Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol e-pub ahead of print. doi: 10.1007/s00280-010-1283-3
13. JJ Shah DJ Kuhn RZ Orlowski 2009 Bortezomib and EGCG: no green tea for you? Blood 113 5695 5696 19498025 10.1182/blood-2009-03-204776 1:CAS:528:DC%2BD1MXnsVSks7w%3D
14. JD Lambert MJ Lee H Lu, et al. 2003 Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice J Nutr 133 4172 4177 14652367 1:CAS:528:DC%2BD3sXpslGmur8%3D (Pubitemid 37505494)
15. HH Chow IA Hakim DR Vining, et al. 2005 Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals Clin Cancer Res 11 4627 4633 15958649 10.1158/1078-0432.CCR-04-2549 1:CAS:528:DC%2BD2MXltFeksLY%3D (Pubitemid 40825654)
16. HH Chow Y Cai IA Hakim, et al. 2003 Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals Clin Cancer Res 9 3312 3319 12960117 1:CAS:528:DC%2BD3sXotFCksLY%3D (Pubitemid 37082725)
17. JD Lambert MJ Lee L Diamond, et al. 2006 Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues Drug Metab Dispos 34 8 11 16204466 10.1124/dmd.104.003434 1:CAS:528:DC%2BD28XhslOqtg%3D%3D (Pubitemid 43042639)
18. SJ Padayatty H Sun Y Wang, et al. 2004 Vitamin C pharmacokinetics: implications for oral and intravenous use Ann Intern Med 140 533 537 15068981 1:CAS:528:DC%2BD2cXjsFSqsrw%3D
19. MJ Williamson MD Silva J Terkelsen, et al. 2009 The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models Mol Cancer Ther 8 3234 3243 19934276 10.1158/1535-7163.MCT-09-0239 1:CAS:528:DC%2BD1MXhsFCitbzF
20. E Kupperman EC Lee Y Cao, et al. 2010 Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res 70 1970 1980 20160034 10.1158/0008-5472.CAN-09-2766 1:CAS:528:DC%2BC3cXisFWisro%3D
21. CS Tsao PY Leung M Young 1987 Effect of dietary ascorbic acid intake on tissue vitamin C in mice J Nutr 117 291 297 3559744 1:CAS:528:DyaL2sXktVKitbs%3D (Pubitemid 17047075)
22. J Lykkesfeldt S Loft JB Nielsen HE Poulsen 1997 Ascorbic acid and dehydroascorbic acid as biomarkers of oxidative stress caused by smoking Am J Clin Nutr 65 959 963 9094879 1:CAS:528:DyaK2sXitlamsbc%3D (Pubitemid 27152611)